In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.
Arthritis Patients More Likely to Stick With Biosimilars
Spanish patients with various forms of inflammatory arthritis who started either etanercept or adalimumab were more likely to continue taking them if they were biosimilar
September 4, 2024